IP Library › Patent Application 14199144
Patent Application
App. No. 14/199,144

Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/199,144
Abstract

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

Claims (21)

1 . A locally deliverable composition for inhibiting pain/inflammation and spasm, comprising a combination of ketoprofen and a calcium channel antagonist in a carrier, each of the ketoprofen and the calcium channel antagonist included in a therapeutically effective amount such that the combination inhibits pain/inflammation and spasm at a site of local delivery.

2 . The composition of claim 1 , wherein the calcium channel antagonist comprises an L-type calcium channel antagonist.

3 . The method of claim 2 , wherein the L-type calcium channel antagonist is selected from the group consisting of verapamil, diltiazem, bepridil, mibefradil, nifedipine, nicardipine, isradipine, amlodipine, felodipine, nisoldipine and nimodipine.

4 . The method of claim wherein the L-type calcium channel antagonist comprises a dihydropyridine.

5 . The composition of claim 4 , wherein the L-type calcium channel antagonist is selected from the group consisting of nifedipine, nicardipine, isradipine, amlodipine, felodipine, nisoldipine and nimodipine.

6 . The method of claim 5 , wherein the L-type calcium channel antagonist comprises nifedipine.

7 . The composition of claim 5 , wherein the L-type calcium channel antagonist has an onset of action of less than or equal to 10 minutes.

8 . The composition of claim 1 , wherein the calcium channel antagonist comprises nifedipine.

9 . The composition of claim 8 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of from 10:1 to 1:10.

10 . The composition of claim 9 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of from 4:1 to 1:1.

11 . The composition of claim 10 , wherein ketoprofen and nifedipine are included in the composition in a ketoprofen:nifedipine molar ratio of 3:1.

12 . The composition of claim 8 , wherein ketoprofen is included in the composition at a concentration of no more than 500,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 200,000 nanomolar.

13 . The composition of claim 12 , wherein ketoprofen is included in the composition at a concentration of no more than 300,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 100,000 nanomolar.

14 . The composition of claim 13 , wherein ketoprofen is included in the composition at a concentration of no more than 50,000 nanomolar and nifedipine is included in the composition at a concentration of no more than 25,000 nanomolar.

15 . The composition of claim 1 , wherein ketoprofen is included in the composition at a concentration of no more than 500,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 200,000 nanomolar.

16 . The composition of claim 15 , wherein ketoprofen is included in the composition at a concentration of no more than 300,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 100,000 nanomolar.

17 . The composition of claim 16 , wherein ketoprofen is included in the composition at a concentration of no more than 50,000 nanomolar and the calcium channel antagonist is included in the composition at a concentration of no more than 25,000 nanomolar.

18 . The composition of claim 1 , wherein ketoprofen comprises the S-(+)-enantiomer, dexketoprofen.

19 . The composition of claim 1 , wherein the composition is coated onto an implantable device or medical instrument.

20 . The composition of claim 1 , wherein the composition is impregnated into an implantable device or medical instrument.

21 - 54 . (canceled)